International Scholarly Research Notices / 2012 / Article / Tab 2

Clinical Study

Efficacy and Tolerability of Clarema 1% Cream and Hirudoid 40000 U.APTT Gel in the Topical Treatment of Haematomas and/or Subcutaneous Haematic Extravasations

Table 2

Subjective symptoms and objective signs of haematomas/extravasations (secondary efficacy variables).
(a)

ParameterMean decrease from baseline to endpoint
Mean [95% CI]Differences between the adjusted means [95% CI]
Heparan sulfateGAGPS

Pain at rest−1.2 [−1.4 to −1.1]−1.1 [−1.3 to −1.0]0.02 [0.07 to 0.11]
Pain on movement−1.9 [−2.0 to −1.7]−1.4 [−1.6 to −1.1]0.53 [0.27 to 0.78]
Functional disability−1.6 [−1.8 to −1.4]−1.3 [−1.5 to −1.1]0.39 [0.09 to 0.68]
Oedema−2.3 [−2.5 to −2.1]−1.9 [−2.2 to −1.7]0.41 [0.19 to 0.63]
Colour of the lesion−2.8 [−2.9 to −2.7]−2.1 [−2.3 to −2.0]0.64 [0.42 to 0.87]

Size of the lesion

Minimum diameter−5.1 [−5.8 to −4.5]−3.9 [−4.6 to −3.2]1.48 [0.88 to 2.08]
Maximum diameter−8.0 [−8.8 to −7.2]−5.9 [−6.9 to −4.8]2.25 [1.37 to 3.14]
Product of min*max diameter−50.5 [−59.5 to −41.5]−50.2 [−65.9 to −34.6]5.95 [1.35 to 10.56]

(b)

ParameterComplete disappearance
𝑛 (%)Fisher’s exact test
Heparan sulfateGAGPS

Pain at rest46 (95.8)45 (93.8)NS
Pain on movement30 (62.5)11 (22.9)<0.0001
Functional disability30 (62.5)15 (31.3)0.0015
Oedema43 (89.6)28 (58.3)<0.0001
Colour of the lesion38 (79.2)15 (31.3)<0.0001

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.